Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study

Basit Öğe Kaydı
dc.contributor.authorAkinci, M. Bulent
dc.contributor.authorAlgin, E.
dc.contributor.authorInal, A.
dc.contributor.authorOdabas, H.
dc.contributor.authorBerk, V.
dc.contributor.authorCoskun, U.
dc.contributor.authorUyeturk, U.
dc.date.accessioned2024-04-24T17:38:02Z
dc.date.available2024-04-24T17:38:02Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose: Anthracyclines and taxanes are the most active agents in the adjuvant treatment of breast cancer (BC). They can be used simultaneously or sequentially. The optimal schedule and duration for their administration is unknown. We analyzed the efficacy of sequential adjuvant anthracycline and docetaxel administration in node positive BC patients. Methods: Node positive BC patients (N=539) from 6 medical oncology centers in Turkey who received sequential adjuvant anthracycline-based regimens and taxane chemotherapy were included in this study between 2006 - 2010. One-hundred and thirty-eight (25%) patients received 3 cycles of anthracycline-based chemotherapy followed by 3 cycles of docetaxel (3+3) and 401 (75%) patients received 4 cycles of anthracycline-based chemotherapy followed by 4 cycles of docetaxel (4+4). Prognostic factors analyzed were estrogen receptor (ER), progesterone receptor (PR), HER2, tumor grade, and nodal status in relation to disease free survival (DFS) and HER2 status in relation to overall survival (OS). Results: The patient median age was 48 years (range 18-79). Most common grade 3-4 toxicities were neutropenia, mucositis and arthralgia. No treatment-related toxic deaths were seen. With a median follow up of 26 months (range 1-115) 61 (11.3%) recurrences and 11 (2%) deaths were registered. Three-year DFS was 81% and OS 96% for all patients. There was no statistically significant difference between 3+3 and 4+4 groups in terms of survival (3-year DFS 88% and 79% [p=0.28] and OS 97% and 95% [p=0.60] respectively). Conclusion: Sequential chemotherapy with 4+4 cycles of anthracycline and docetaxel every 3 weeks is an acceptable regimen for adjuvant treatment of node positive BC patients. Duration of chemotherapy should be planned depending on prognostic factors. In this study there was no difference between 3+3 and 4+4 groups in DFS and OS despite the presence of good prognostic factors in the 3+3 group.en_US
dc.identifier.endpage320en_US
dc.identifier.issn1107-0625
dc.identifier.issue2en_US
dc.identifier.pmid23818340
dc.identifier.scopus2-s2.0-84879586665
dc.identifier.scopusqualityQ3
dc.identifier.startpage314en_US
dc.identifier.urihttps://hdl.handle.net/11468/21296
dc.identifier.volume18en_US
dc.identifier.wosWOS:000322750700002
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherZerbinis Medical Publen_US
dc.relation.ispartofJournal of Buon
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdjuvanten_US
dc.subjectAnthracyclineen_US
dc.subjectBreast Canceren_US
dc.subjectDocetaxelen_US
dc.subjectNode Positiveen_US
dc.titleSequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective studyen_US
dc.titleSequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu